Beam Therapeutics Inc.
BEAM-302
alpha-1 antitrypsin deficiency (AATD)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on BEAM-302 for alpha-1 antitrypsin deficiency (AATD) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“Beam expects to initiate this pivotal cohort in the second half of 2026.”